))
Neurology Edition: Top Headlines for Week of May 23, 2023
Manage episode 407442270 series 3560281
内容由Healio提供。所有播客内容（包括剧集、图形和播客描述）均由 Healio 或其播客平台合作伙伴直接上传和提供。如果您认为有人在未经您许可的情况下使用您的受版权保护的作品，您可以按照此处概述的流程进行操作https://zh.player.fm/legal。
In this edition, FDA approves supplemental new drug application for Rexulti, early amyloid PET provides high diagnostic confidence, Leqembi reduced biomarkers of Alzheimer’s and more.
Read the full coverage here:
FDA approves supplemental new drug application for Rexulti to treat Alzheimer's agitation
Early amyloid PET provides high diagnostic confidence for adults with cognitive impairment
Leqembi reduced biomarkers of Alzheimer’s, slowed cognitive decline at 18 months
FDA grants 510(k) clearance for self-directed EEG headset
Oral Bruton’s tyrosine kinase inhibitor reduced brain lesions in phase 2 MS trial
References:
Altomare D, et al. JAMA Neurol. 2023;doi:10.1001/jamaneurol.2023.0997.
Van Dyck CH, et al. A study to confirm safety and efficacy of lecanemab in participants with early Alzheimer’s disease (Clarity AD). Presented at: American Academy of Neurology annual meeting; April 22-27, 2023; Boston.
108集单集
分享
